IDEAYA Biosciences, Inc. (IDYA): Lienzo del Modelo de Negocios [Actualizado en Ene-2025]

En el mundo de vanguardia de la oncología de precisión, Ideeya Biosciences, Inc. (Idya) emerge como una fuerza transformadora, pionero en enfoques terapéuticos innovadores que aprovechan los principios innovadores de la letalidad sintética. Al navegar estratégicamente el complejo panorama de la identificación del objetivo molecular y los tratamientos personalizados contra el cáncer, esta potencia biotecnología está redefiniendo cómo entendemos y combatemos el cáncer, ofreciendo esperanza a través de su sofisticada biología computacional y metodologías de investigación específicas. Sumérgete en el intrincado lienzo de modelo de negocio que revela cómo Ideeya no solo está desarrollando drogas, sino revolucionando todo el paradigma de la investigación y el tratamiento oncológicos.

Ideeya Biosciences, Inc. (Idya) - Modelo de negocios: asociaciones clave

Colaboración estratégica con compañías farmacéuticas para el desarrollo de medicamentos

Ideeya Biosciences ha establecido asociaciones farmacéuticas críticas a partir de 2024:

Pareja	Enfoque de colaboración	Términos financieros
GSK (GlaxoSmithKline)	Programa de ADN Helicasa de WRN	Pago por adelantado de $ 15 millones
Bristol Myers Squibb	Terapéutica oncológica de precisión	Financiación de colaboración inicial de $ 20 millones

Asociaciones de investigación con instituciones académicas y centros de investigación del cáncer

Las colaboraciones clave de la investigación académica incluyen:

• Universidad de California, San Francisco (UCSF) - Identificación del objetivo molecular
• Centro de Cáncer de Stanford - Investigación de oncología de precisión
• Memorial Sloan Kettering Cancer Center - Estudios de validación terapéutica

Acuerdos de licencia para la identificación y validación del objetivo molecular

Acuerdos de licencia de Ideeya a partir de 2024:

Licenciante	Tecnología/objetivo	Costo de licencia
Instituto del Cáncer Dana-Farber	Nuevos objetivos de respuesta al daño del ADN	Licencia exclusiva de $ 5.2 millones
Escuela de Medicina de Harvard	Plataforma de detección de letalidad sintética	Licencia de tecnología de $ 3.8 millones

Asociaciones de desarrollo de colaboración en Terapéutica de Oncología de Precisión

Asociaciones actuales de co-desarrollo:

• Merck - Desarrollo del inhibidor de CDK7 IDE397
• AstraZeneca - Descubrimiento de drogas de letalidad sintética
• Pfizer - Colaboración terapéutica de respuesta al daño de ADN

Ideeya Biosciences, Inc. (Idya) - Modelo de negocios: actividades clave

Identificación del objetivo molecular en letalidad sintética

Ideya se centra en identificar objetivos de letalidad sintética con precisión. A partir de 2024, la compañía tiene 4 programas de letalidad sintética activa en su tubería.

Enfoque del programa	Etapa actual	Área terapéutica
Letalidad sintética parp/polq	Preclínico	Oncología
Programa WRN helicasa	Descubrimiento	Oncología de precisión

Descubrimiento y desarrollo de fármacos preclínicos y clínicos

Los esfuerzos de descubrimiento de drogas de Ideeya se concentran en enfoques terapéuticos innovadores.

• Inversión total de I + D en 2023: $ 54.2 millones
• Número de programas activos de descubrimiento de fármacos: 6
• Ensayos clínicos en progreso: 2 programas de etapa clínica

Biología computacional e investigación genómica

La Compañía aprovecha técnicas computacionales avanzadas para la identificación de objetivos.

Tecnología de investigación	Solicitud	Recursos computacionales
Cribado objetivo impulsado por IA	Identificación de letalidad sintética	Clúster informático de alto rendimiento

Innovación terapéutica centrada en la oncología

Ideeya se especializa en el desarrollo terapéutico oncológico de precisión.

• Programas de oncología: 4 programas terapéuticos primarios
• Tipos de cáncer dirigido: tumores sólidos, mutaciones de cáncer genético
• Socios de colaboración: 2 asociaciones de investigación farmacéutica

Investigación y desarrollo de enfoques de medicina de precisión

El desarrollo de la medicina de precisión sigue siendo un enfoque estratégico central.

Enfoque de medicina de precisión	Enfoque de investigación	Etapa de desarrollo
Orientación de mutación genética	Vías de respuesta al daño del ADN	Avanzado preclínico

Ideeya Biosciences, Inc. (Idya) - Modelo de negocio: recursos clave

Plataforma de descubrimiento de letalidad sintética patentada

A partir del cuarto trimestre de 2023, Ideeya ha desarrollado un plataforma de oncología de precisión centrado en la letalidad sintética y la terapéutica dirigida.

Métrica de plataforma	Datos cuantitativos
Inversión de investigación	$ 24.7 millones en gastos de I + D (informe anual de 2022)
Cartera de patentes	12 patentes otorgadas a diciembre de 2023

Equipo experimentado de liderazgo científico y de investigación

• Dr. Yujiro Hoshijima - Director Científico
• Dr. Mitchell Gold - Cofundador y CEO
• Equipo de liderazgo total: 7 ejecutivos altos

Capacidades avanzadas de investigación computacional y genómica

IDEYA utiliza Técnicas avanzadas de biología computacional para el descubrimiento de drogas.

Capacidad de investigación	Especificación
Infraestructura computacional	Sistemas informáticos de alto rendimiento con capacidades de análisis genómico
Equipo bioinformático	12 biólogos computacionales especializados

Cartera de propiedades intelectuales

Centrado en la terapéutica dirigida en oncología.

Categoría de IP	Número
Solicitudes de patentes totales	18 aplicaciones pendientes
Patentes concedidas	12 patentes emitidas

Instalaciones de investigación e infraestructura de laboratorio

• Ubicación de investigación principal: South San Francisco, California
• Espacio total de la instalación de investigación: aproximadamente 25,000 pies cuadrados
• Inversión de equipos de laboratorio: $ 4.3 millones en 2022

Valoración total de recursos clave: estimado $ 52.1 millones en activos tangibles e intangibles (informe financiero de 2022).

Ideeya Biosciences, Inc. (Idya) - Modelo de negocio: propuestas de valor

Enfoques terapéuticos oncológicos de precisión innovadores

Ideeya Biosciences se centra en desarrollar terapias de cáncer dirigidas con características moleculares específicas. A partir del cuarto trimestre de 2023, la compañía tenía 3 programas de oncología de precisión de etapa clínica en desarrollo.

Programa	Escenario	Indicación objetivo
IDE397	Fase 1/2	Inhibidor de PARP7
IDE161	Preclínico	Inhibidor de helicasa WRN
IDE196	Fase 2	Inhibidor de PKC

Tratamientos dirigidos que abordan las necesidades médicas no satisfechas

La tubería de investigación de la compañía se dirige a vulnerabilidades genéticas específicas en el cáncer, con un enfoque en los enfoques de letalidad sintética.

• La orientación de letalidad sintética representa una oportunidad de mercado potencial de $ 12.7 mil millones
• Se espera que el mercado de oncología de precisión alcance los $ 186.7 mil millones para 2028
• Población estimada de pacientes direccionables: aproximadamente 30,000-50,000 anuales

Potencial para terapias de cáncer más efectivas y menos tóxicas

La estrategia terapéutica de Ideeya tiene como objetivo minimizar los efectos secundarios al tiempo que maximiza la eficacia del tratamiento. La inversión de investigación en 2023 fue de $ 67.4 millones dedicada al desarrollo de medicamentos oncológicos.

Desarrollo de tratamientos dirigidos moleculares personalizados

Objetivo molecular	Enfoque terapéutico	Potencial de población de pacientes
Parp7	Letalidad sintética	Tumores sólidos con mutaciones genéticas específicas
WRN helicasa	Respuesta al daño del ADN	Cánceres de inestabilidad de microsatélites

Enfoque científico avanzado aprovechando los principios de letalidad sintética

La estrategia científica de Ideeya se centra en identificar y atacar vulnerabilidades genéticas específicas en las células cancerosas. A partir de 2023, la compañía tenía 37 solicitudes de patentes y 12 patentes emitidas que respaldan su plataforma de oncología de precisión.

• Gastos de I + D en 2023: $ 67.4 millones
• Efectivo e inversiones a partir del tercer trimestre de 2023: $ 295.1 millones
• Capitalización de mercado (enero de 2024): aproximadamente $ 628 millones

Ideeya Biosciences, Inc. (Idya) - Modelo de negocios: relaciones con los clientes

Compromiso directo con socios de investigación farmacéutica

A partir del cuarto trimestre de 2023, Ideeya Biosciences informó 2 asociaciones de colaboración farmacéutica activa con socios de investigación estratégica.

Pareja	Tipo de colaboración	Valor de colaboración
Gsk	Asociación de oncología de precisión	$ 90 millones de pago por adelantado
Merck	Investigación de letalidad sintética	Financiación de colaboración inicial de $ 55 millones

Conferencia científica y participación en eventos de la industria

Ideeya participó en 7 principales conferencias de oncología y medicina de precisión en 2023.

• Reunión anual de la Asociación Americana de Investigación del Cáncer (AACR)
• Congreso de la Sociedad Europea de Oncología Médica (ESMO)
• Simposio de cáncer de mama de San Antonio

Estrategias de comunicación de inversores y partes interesadas

Métricas trimestrales de informes financieros para 2023:

Canal de comunicación	Frecuencia	Alcanzar
Llamadas de ganancias	4 veces anualmente	Más de 150 inversores institucionales
Presentaciones de inversores	6-8 por año	Aproximadamente 200 analistas financieros

Interacciones colaborativas de investigación y desarrollo

Investigación de métricas de colaboración para 2023:

• Colaboraciones totales de I + D: 3 asociaciones activas
• Inversión de investigación: $ 45.2 millones en programas de colaboración
• Colaboraciones de etapa clínica: 2 Iniciativas de oncología de precisión continua

Ensayo clínico transparente e informes de progreso de la investigación

Métricas de informes de ensayos clínicos para 2023:

Plataforma de informes	Número de actualizaciones	Alcance de visibilidad
Clinicaltrials.gov	12 actualizaciones completas	Más de 50,000 profesionales médicos
Sitio web de la empresa	8 Informes detallados de progreso de la investigación	Aproximadamente 25,000 partes interesadas

Ideeya Biosciences, Inc. (Idya) - Modelo de negocios: canales

Publicaciones científicas y revistas revisadas por pares

A partir del cuarto trimestre de 2023, Ideeya Biosciences publicó 7 artículos científicos revisados ​​por pares en revistas como Nature, Cancer Discovery y Molecular Cancer Therapeutics.

Diario	Número de publicaciones	Factor de impacto
Naturaleza	2	49.962
Descubrimiento de cáncer	3	33.415
Terapéutica del cáncer molecular	2	5.636

Conferencias de la industria de biotecnología y oncología

En 2023, Ideeya participó en 12 principales conferencias de biotecnología y oncología.

• Reunión anual de ASCO
• Reunión anual de AACR
• Simposio de cáncer de mama de San Antonio
• Congreso de la Sociedad Europea de Oncología Médica

Equipos directos de ventas y desarrollo de negocios

El equipo de ventas de Ideeya consta de 18 profesionales a diciembre de 2023, centrándose en asociaciones estratégicas y posibles oportunidades de licencia.

Segmento de equipo	Número de profesionales
Desarrollo comercial	8
Ventas directas	10

Plataformas de comunicación digital

Ideeya mantiene la presencia digital activa en múltiples plataformas.

Plataforma	Seguidores/conexiones
LinkedIn	15,234
Gorjeo	8,765
Sitio web corporativo	52,341 visitantes mensuales

Comunicaciones de relaciones con los inversores

Ideeya realizó 42 reuniones de inversores y llamadas de conferencia en 2023, con un total de 187 inversores institucionales comprometidos.

Tipo de comunicación	Frecuencia en 2023
Llamadas de ganancias trimestrales	4
Conferencias de inversores	6
Reuniones individuales	32

Ideeya Biosciences, Inc. (Idya) - Modelo de negocios: segmentos de clientes

Organizaciones de investigación farmacéutica

Ideeya Biosciences se dirige a organizaciones de investigación farmacéutica con enfoque específico en oncología de precisión y plataformas de letalidad sintética.

Tipo de organización	Escala de colaboración potencial	Enfoque de investigación
Grandes compañías farmacéuticas	$ 5-10 millones por asociación de investigación	Desarrollo de medicamentos oncológicos de precisión
Firmas de investigación farmacéutica de tamaño mediano	$ 1-3 millones por colaboración de investigación	Estrategias terapéuticas dirigidas

Centros de tratamiento oncológico

Ideeya se centra en los centros de tratamiento de oncología especializados en investigación avanzada del cáncer y medicina personalizada.

• Centros afiliados de la Red Nacional de Cáncer Integral (NCCN)
• Centros médicos académicos con programas de investigación oncológica
• Instalaciones especializadas de tratamiento del cáncer

Instituciones de investigación académica

Ideeya colabora con instituciones de investigación académica que desarrollan una innovadora terapéutica del cáncer.

Tipo de institución	Inversión de investigación potencial	Áreas de colaboración
Universidades de investigación de primer nivel	$ 2-4 millones por programa de investigación	Plataformas de letalidad sintética
Centros de investigación del cáncer	$ 1-2 millones por proyecto colaborativo	Desarrollo oncológico de precisión

Inversores de biotecnología

Ideeya atrae a los inversores de biotecnología a través de su innovadora canalización de oncología de precisión.

• Empresas de capital de riesgo especializadas en inversiones en biotecnología
• Inversores institucionales centrados en la terapéutica oncológica
• Grupos de capital privado con carteras de ciencias de la vida

Fundamentos de investigación del cáncer

Ideeya se involucra con fundaciones de investigación del cáncer que apoyan el desarrollo terapéutico avanzado.

Tipo de base	Soporte de financiación potencial	Interés de investigación
National Cancer Research Foundations	$ 500,000- $ 1.5 millones por subvención de investigación	Estrategias innovadoras de tratamiento del cáncer
Fundaciones privadas de investigación del cáncer	$ 250,000- $ 750,000 por iniciativa de investigación	Avances oncológicos de precisión

Ideeya Biosciences, Inc. (Idya) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal que finalizó el 31 de diciembre de 2022, Ideeya Biosciences reportó gastos de I + D de $ 86.1 millones.

Año fiscal	Gastos de I + D	Aumento porcentual
2021	$ 62.4 millones	37.8%
2022	$ 86.1 millones	38.0%

Costos de desarrollo clínico y desarrollo de medicamentos

Los costos de desarrollo clínico de Ideeya para los programas de oncología de precisión fueron de $ 45.3 millones en 2022.

• Costos de desarrollo del programa IDE397: $ 18.2 millones
• Costos de desarrollo del programa IDE196: $ 22.5 millones
• Otros programas preclínicos: $ 4.6 millones

Protección y mantenimiento de la propiedad intelectual

Los gastos anuales de protección de la propiedad intelectual fueron de aproximadamente $ 2.1 millones en 2022.

Reclutamiento y retención de talento científico

Categoría de gastos	Cantidad
Salarios y salarios	$ 37.6 millones
Compensación basada en acciones	$ 12.4 millones
Gastos totales de personal	$ 50.0 millones

Inversiones de equipos e tecnología de laboratorio

Los gastos de capital para equipos y tecnología de laboratorio en 2022 totalizaron $ 5.7 millones.

• Equipo de detección molecular avanzado: $ 2.3 millones
• Infraestructura de biología computacional: $ 1.8 millones
• Plataformas de detección de alto rendimiento: $ 1.6 millones

Ideeya Biosciences, Inc. (Idya) - Modelo de negocios: flujos de ingresos

Pagos potenciales de hitos de acuerdos de colaboración

A partir de 2024, Ideeya Biosciences tiene acuerdos de colaboración activos con socios farmacéuticos clave:

Pareja	Pagos potenciales de hitos	Área de investigación
Merck & Co.	Pagos potenciales de hitos potenciales de $ 270 millones	Programas de respuesta al daño del ADN (DDR)
Gsk	$ 120 millones de pagos potenciales de hito	Programas de letalidad sintética

Ingresos de licencia de propiedad intelectual

La estrategia de licencia de propiedad intelectual de Ideeya incluye:

• Licencias exclusivas de los candidatos de drogas de letalidad sintética
• Portafolio de patentes que cubre múltiples objetivos terapéuticos de oncología
• Los posibles ingresos de licencia estimados en $ 50-75 millones anuales

Subvenciones de investigación y financiación del gobierno

Fuentes de financiación para 2024:

Fuente de financiación	Cantidad	Objetivo
NIH Subvenciones	$ 4.2 millones	Apoyo de investigación oncológica
Subvenciones SBIR/STTR	$ 1.8 millones	Investigación de innovación de pequeñas empresas

Posibles regalías potenciales de drogas

Potencial proyectado de regalías de drogas:

• IDE196: Las regalías potenciales rango 8-12% de las ventas netas
• IDE161: Potencial de regalías estimado de $ 30-50 millones anuales

Actividades de financiamiento de capital y recaudación de capital

Detalles de recaudación de capital para 2024:

Método de financiación	Cantidad recaudada	Fecha
Ofrenda pública	$ 85.5 millones	Enero de 2024
Colocación privada	$ 45.2 millones	Marzo de 2024

IDEAYA Biosciences, Inc. (IDYA) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a patient, physician, or payer would choose IDEAYA Biosciences, Inc. (IDYA)'s approach over the standard of care. It's all about delivering targeted efficacy where current options fall short.

Potential first-in-class/best-in-class targeted therapies for solid tumors

IDEAYA Biosciences, Inc. is building a pipeline focused on precision oncology, leveraging synthetic lethality and antibody-drug conjugates (ADCs) to hit molecularly defined targets. This focus aims to deliver therapies that are more selective and effective than broad-spectrum treatments.

The company has several programs advancing, with three IND submissions on track by year-end 2025, potentially bringing their clinical-stage precision oncology programs to nine.

Addressing high unmet needs in genetically-defined cancers (e.g., GNAQ/11-mutant Uveal Melanoma)

For GNAQ or GNA11 mutations, which activate PKC signaling in greater than 90% of uveal melanoma (UM) cases, there are currently no approved systemic therapies for the primary UM setting. This represents a critical unmet need where the standard of care often involves organ removal.

The value proposition here is demonstrated by the Phase 2 OptimUM-09 trial data for neoadjuvant darovasertib in primary UM, presented at ESMO 2025:

Efficacy Metric	Cohort 1 (EN Recommended) Data	Cohort 2 (PB Eligible) Data
Patients Evaluated (as of June 13, 2025)	56	39
Overall Ocular Tumor Shrinkage (any)	83% (of 94 total patients)	82% (of total patients)
Tumor Shrinkage $\ge$20%	50% (of Cohort 1) or 54% (of 94 total)	60.5%
Eye Preservation Rate (Post-Local Therapy)	57% (of 42 patients)	N/A
Eye Preservation Rate with $\ge$20% Tumor Shrinkage	95% (of 20 patients)	N/A

Organ preservation strategy via neoadjuvant therapy (darovasertib in primary UM)

The strategy with darovasertib is to provide systemic tumor control before definitive local treatment, aiming to reduce the need for enucleation (EN) or high-dose radiation, which often leads to vision loss. This is a paradigm shift from the current standard.

For patients eligible for plaque brachytherapy (PB), the therapy showed a potential to reduce long-term risk:

• 70% achieved a reduction in predicted radiation dose to key eye structures.
• 65% showed a decreased predicted risk of legal blindness 3-years post-PB treatment.
• Approximately 55% of EN eligible patients demonstrated an improvement in baseline visual acuity scores (VAS), with a mean gain of 17 letters.

The U.S. FDA granted Breakthrough Therapy Designation to darovasertib in this neoadjuvant setting, underscoring its potential to be the first systemic therapy to meaningfully prevent eye removal.

Exploiting synthetic lethality to target historically undruggable oncogenic pathways

IDEAYA Biosciences, Inc. is building a deep pipeline based on synthetic lethality, which targets specific vulnerabilities created by the loss of a tumor suppressor gene. This approach is designed to be highly selective.

Key synthetic lethality programs include:

• PKC inhibition (Darovasertib) for GNAQ/GNA11 mutations in UM.
• MAT2A inhibition (IDE397) for tumors with MTAP gene deletion.
• Pol Theta inhibition for tumors with double-strand break repair defects, such as BRCA1 or BRCA2 mutations, in collaboration with GSK.

Providing molecularly-defined treatment options for patients with MTAP deletion (approx. 15% of solid tumors)

The MTAP deletion biomarker defines a patient population that is vulnerable to inhibition of the MAT2A enzyme, a synthetic lethality target. This deletion occurs in approximately 15% of all solid tumors.

The prevalence of MTAP homozygous deletion varies, but significant frequencies are seen in specific tumor types:

• Glioblastoma: 26% to 60%.
• Bladder cancer: 16.9%.
• Mesothelioma: 17.7%.

IDEAYA Biosciences, Inc. is advancing IDE397, a MAT2A inhibitor, for this molecularly-defined group, which is associated with a poor prognosis in cancers like pancreatic ductal adenocarcinoma, NSCLC, gastric cancer, and glioblastoma.

The company's financial footing supports this development, with approximately $991.9 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which is anticipated to fund operations into 2029.

IDEAYA Biosciences, Inc. (IDYA) - Canvas Business Model: Customer Relationships

High-touch, collaborative relationships with major pharmaceutical partners are central to IDEAYA Biosciences, Inc.'s development strategy, de-risking assets and expanding geographic reach.

The exclusive license agreement with Servier for darovasertib rights outside the United States brought in $210 million upfront cash as of the third quarter of 2025, with an additional potential of up to $320 million in milestone payments. IDEAYA Biosciences, Inc. also has ongoing collaborations, such as the one with GSK for IDE705 (Pol Theta inhibitor). However, in December 2025, GlaxoSmithKline Intellectual Property elected to terminate the Collaboration, Option and License Agreement for the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs. Furthermore, Hengrui Pharma is a partner conducting a Phase 1 clinical trial for IDE849 in China.

Partner	Program(s)	Financial/Status Detail (as of late 2025)
Servier	Darovasertib (ex-US)	Received $210 million upfront; eligible for up to $320 million in milestones
Hengrui Pharma	IDE849 (DLL3 TOP1i ADC)	Conducted Phase 1 trial in China; presented data on 87 SCLC and 13 NEC patients
GSK	IDE275, IDE705	Agreement terminated in December 2025

Direct engagement with key opinion leaders and clinical investigators is evidenced by the cadence of clinical data presentations at major medical conferences throughout 2025.

• Phase 2 data from over 90 primary uveal melanoma (UM) patients treated with darovasertib in the neoadjuvant setting were shared at ESMO in 4Q 2025.
• First-in-human Phase 1 data from over 70 SCLC patients treated with IDE849 were presented at the IASLC 2025 World Conference on Lung Cancer on September 7th, 2025.
• The single-arm Phase 2 trial (OptimUM-01) evaluating darovasertib/crizotinib in 1L mUM reported median overall survival (OS) of 21.1 months among 44 patients.
• The randomized Phase 2 trial (OptimUM-09) data included a total of 95 patients (56 enucleation-recommended and 39 plaque brachytherapy-eligible).

Proactive communication with the investment community is structured around regular financial updates and participation in key industry forums.

IDEAYA Biosciences, Inc. reported its third quarter 2025 financial results on November 4, 2025. As of September 30, 2025, the company held approximately $1.14 billion in cash, cash equivalents, and marketable securities. This position provided an expected cash runway into 2030 following the Servier deal. The President and Chief Executive Officer participated in the Citi's 2025 Global Healthcare Conference on December 2nd, 2025, and the Evercore Healthcare Conference on December 3rd, 2025.

Regulatory management and interaction with health authorities, primarily the U.S. Food and Drug Administration (FDA), drive key development timelines.

• The darovasertib program received U.S. FDA Breakthrough Therapy Designation for neoadjuvant use in UM patients facing enucleation.
• A successful FDA Type D meeting was completed to finalize the darovasertib Phase 3 registrational trial design.
• The company targeted three IND submissions in 2025.
• IND clearance for IDE892 (PRMT5) was received in 3Q 2025.
• IND clearance for IDE034 was announced on December 1, 2025.
• The IND filing for IDE034 was complete, with the IND filing for IDE574 (KAT6/7) on track for year-end 2025.

IDEAYA Biosciences, Inc. (IDYA) - Canvas Business Model: Channels

You're looking at how IDEAYA Biosciences, Inc. gets its therapies and data out to the world, which is a mix of direct engagement and strategic partnerships. It's not just about the lab; it's about the agreements and the data dissemination that drive the business forward.

Out-licensing agreements to partners (e.g., Servier) for ex-US commercialization

IDEAYA Biosciences, Inc. uses out-licensing for global reach, especially outside the US. A key example is the agreement for darovasertib.

• Entered into an exclusive license agreement with Servier for rights to darovasertib outside the United States in the third quarter of 2025.
• The Servier deal provided IDEAYA Biosciences, Inc. with $210 million upfront cash.
• IDEAYA Biosciences, Inc. is eligible to receive up to $320 million in milestone payments from Servier.
• IDEAYA Biosciences, Inc. also has an exclusive global license agreement for IDE849 outside of Greater China with Hengrui Pharma, established in December 2024.

Global network of clinical trial sites and investigators for drug delivery to patients

The delivery of investigational drugs to patients relies on a network of ongoing clinical trials across different geographies and indications. This is how the data gets generated.

Trial/Program	Patient Count/Status	Geography/Context
Darovasertib Phase 2/3 (OptimUM-02)	On track to complete enrollment of approximately 400 patients by year-end 2025.	Registration-enabling trial for 1L HLAA2-negative metastatic uveal melanoma (mUM).
Darovasertib Phase 2 (OptimUM-09)	Data presented from a total of 95 primary UM patients as of June 13, 2025.	Neoadjuvant setting of primary Uveal Melanoma (UM).
IDE849 (DLL3 TOP1i ADC) Phase 1	Hengrui Pharma presented data from over 70 SCLC patients at WCLC 2025.	Conducted by partner Hengrui Pharma in China.
IDE275 (GSK959) Phase 1	Dose escalation is ongoing.	Patients with MSI-High solid tumors.

The Phase 3 registration-enabling trial for darovasertib, OptimUM-10, initiated in Q3 2025, is planned to enroll approximately 520 patients in total. That's a significant commitment to patient access for this channel.

Presentations at major medical conferences (e.g., ESMO, WCLC) to disseminate clinical data

Disseminating clinical data at top-tier conferences is a primary channel for validating the science and informing the medical community.

• Positive Phase 2 data for darovasertib in neoadjuvant UM were presented in a Proffered Paper oral presentation at ESMO 2025 in October 2025.
• Data from the single-arm, Phase 2 trial (OptimUM-01) of darovasertib/crizotinib were presented at the Society for Melanoma Research (SMR) Congress in October 2025, covering 44 1L mUM patients.
• Phase 1 data for IDE849 (DLL3 TOP1i ADC) were reported at the 2025 World Conference on Lung Cancer (WCLC).
• Initial Phase 1 safety and efficacy data from the IDE397 and Trodelvy® combination trial in MTAP-deletion UC patients were shared at IDEAYA Biosciences, Inc.'s R&D Day on September 8th.

Direct regulatory submissions (IND, NDA) to the FDA and other agencies

Direct engagement with the FDA via regulatory submissions is the critical path to eventual commercialization for wholly-owned assets.

IDEAYA Biosciences, Inc. was on track to submit three Investigational New Drug (IND) applications by the end of 2025:

• IDE892 (PRMT5): Received IND clearance in 3Q 2025.
• IDE034 (B7H3/PTK7 bispecific TOP1i ADC): IND filing was complete as of Q3 2025, with IND clearance received in the third quarter.
• IDE574 (KAT6/7 dual inhibitor): IND filing was on track for year-end 2025.

The company also advanced its darovasertib program by initiating the randomized Phase 3 trial, OptimUM-10, in the third quarter of 2025, following a successful FDA Type D meeting in April 2025. Finance: draft 13-week cash view by Friday.

IDEAYA Biosciences, Inc. (IDYA) - Canvas Business Model: Customer Segments

You're looking at the core groups IDEAYA Biosciences, Inc. (IDYA) targets to drive value from its precision medicine pipeline, as of late 2025. These aren't just patient groups; they are distinct commercial and financial entities that interact with the business model at different stages.

Oncology patients with molecularly-defined solid tumors (e.g., Uveal Melanoma, MTAP-deletion cancers).

This segment represents the ultimate end-user, defined by specific genetic alterations that make them candidates for IDEAYA Biosciences, Inc. (IDYA)'s targeted therapies. For instance, the population with MTAP gene deletion is estimated to represent approximately 15% of all solid tumors. Specifically for IDEAYA Biosciences, Inc. (IDYA)'s IDE397 program, the estimated U.S. MTAP-deletion annual incidence in Urothelial Cancer (UC) and Non-Small Cell Lung Cancer (NSCLC) is approximately 48,000 patients. For the darovasertib program targeting Metastatic Uveal Melanoma (MUM), the patient population harboring GNAQ or GNA11 mutations occurs in greater than 90% of cases. As of August 4, 2025, over 350 patients were enrolled in the combination trial for 1L HLA-A2-negative MUM, with enrollment targeted to complete around 400 patients by year-end 2025. Furthermore, Phase 2 data for neoadjuvant Uveal Melanoma (UM) treatment included over 90 patients treated with darovasertib.

Global pharmaceutical and biotechnology companies seeking late-stage oncology assets.

These are strategic partners who provide validation, funding, and potential commercial reach. IDEAYA Biosciences, Inc. (IDYA) has established Pharma Strategic Partnerships and Collaborations with Pfizer, Gilead, Merck, Hengrui Pharma, Servier, and GSK. A concrete example of a transaction is the exclusive license agreement with Servier for darovasertib rights outside the United States, for which IDEAYA Biosciences, Inc. (IDYA) received $210 million upfront and is eligible for up to $320 million in milestone payments. The collaboration with GSK on Pol Theta and Werner Helicase carries potential for IDEAYA Biosciences, Inc. (IDYA) to earn up to approximately $2 billion in aggregate cash milestones. Hengrui Pharma, a partner, presented clinical data from over 70 Small Cell Lung Cancer (SCLC) patients in their Phase 1 trial for IDE849.

Clinical investigators and oncologists treating rare and common genetically-altered cancers.

These professionals are crucial for executing clinical trials and adopting new standards of care. IDEAYA Biosciences, Inc. (IDYA) is actively driving data readouts that directly inform their practice. For instance, median Progression-Free Survival (PFS) data for the darovasertib/crizotinib combination in 1L HLA-A2-negative MUM is targeted for year-end 2025 or 1Q 2026. Also, clinical program updates for IDE397 in MTAP-deleted UC and NSCLC are planned for the first half of 2026. The company is also advancing IDE849, with partner Hengrui Pharma targeting a clinical data update in over 40 SCLC patients in Q3 2025.

Institutional and individual investors focused on high-growth, clinical-stage biotech.

This segment provides the necessary capital to fund the long-term development of the pipeline. As of September 30, 2025, IDEAYA Biosciences, Inc. (IDYA) reported cash, cash equivalents, and marketable securities of approximately $1.14 billion, with guidance to fund operations into 2030. This follows a cash position of approximately $991.9 million as of June 30, 2025, with a runway into 2029. The company's investor visibility is supported by analyst coverage from firms including JP Morgan, Goldman Sachs, Citi, and Wedbush.

You can see the key intersections of these segments below:

Customer Segment	Key Metric/Data Point	Associated Program/Event
Oncology Patients	~15% of all solid tumors	MTAP-deletion population for IDE397
Oncology Patients	>90% frequency of mutation	GNAQ/GNA11 mutations in Uveal Melanoma
Pharma/Biotech Partners	Upfront Payment: $210 million	Servier license agreement for darovasertib ex-U.S.
Pharma/Biotech Partners	Potential Milestones: Up to $2 billion	GSK collaboration (Pol Theta and Werner Helicase)
Clinical Investigators	Data Presentation: Over 70 patients	IDE849 data in SCLC at WCLC 2025
Investors	Cash Position (Sep 30, 2025): ~$1.14 billion	Funding runway into 2030

The company's engagement with clinical investigators is often formalized through collaborations, such as the one with Gilead for IDE397 in combination with Trodelvy®.

• Oncology patients are defined by biomarkers like GNAQ/GNA11 mutations or MTAP deletion.
• Partnerships are structured to include milestone payments and profit-sharing arrangements.
• The investor base is tracked through analyst coverage from at least 12 firms.
• IND clearances, such as for IDE034 in late 2025, expand the pipeline targeting patients with B7H3/PTK7 expression.

The focus on specific genetic drivers means IDEAYA Biosciences, Inc. (IDYA) is not targeting the entire cancer market, but rather defined subsets, such as the 48,000 estimated annual incidence of MTAP-deletion in UC/NSCLC in the U.S..

IDEAYA Biosciences, Inc. (IDYA) - Canvas Business Model: Cost Structure

You're looking at where IDEAYA Biosciences, Inc. is putting its capital to work, and honestly, it's all about the science right now. For a precision medicine oncology company, the cost structure is heavily weighted toward the front end of drug development.

The single biggest driver of spend is definitely Research and Development (R&D). This is where the heavy lifting happens-preclinical work, running trials, and getting those complex Antibody-Drug Conjugates (ADCs) manufactured.

Here are the key components that make up the cost structure:

• Dominantly Research and Development (R&D) expenses (Q3 2025: $83.0 million).
• Significant clinical trial and CMC manufacturing costs.
• General and Administrative (G&A) expenses, including legal and patent costs (Q1 2025: $13.5 million).
• Personnel and stock-based compensation expenses (Q3 2025 stock comp: $12.2 million).
• Upfront and milestone payments for in-licensed intellectual property.

The R&D spend is not static; it scales with pipeline activity. For example, the R&D expenses for the three months ended September 30, 2025, totaled $83.0 million, up from $74.2 million for the three months ended June 30, 2025. That increase was primarily driven by higher clinical trial and CMC manufacturing expenses to support their programs. That's the cost of moving multiple assets forward.

You can see the breakdown of some of these major cost categories across the first three quarters of 2025 in the table below. Note that G&A includes the necessary overhead to run a growing clinical-stage company, like legal work to protect the intellectual property.

Expense Category	Period Ending March 31, 2025 (Q1 2025)	Period Ending September 30, 2025 (Q3 2025)
Research and Development (R&D) Expenses	$70.9 million	$83.0 million
General and Administrative (G&A) Expenses	$13.5 million	Data not specified in outline
Stock-Based Compensation Expense	$10.2 million	$12.2 million

The upfront payments for IP are lumpy but significant, representing major strategic investments. You saw a one-time $75.0 million upfront payment under the license agreement for IDE849 with Hengrui Pharma that occurred in December 2024, which hit R&D that quarter. More recently, in October 2025, IDEAYA Biosciences received a $210 million upfront payment from Servier for the rights to darovasertib outside the United States. That cash inflow helps offset the ongoing operational burn, but the underlying R&D spend remains high.

To be fair, the G&A line item also reflects growth. For the three months ended March 31, 2025, G&A was $13.5 million, up from $11.0 million in the prior quarter, primarily due to higher personnel-related, consulting, and legal patent expenses supporting that pipeline growth. That's the cost of building out the team to prepare for potential commercialization down the line.

Here's a quick look at the key financial events impacting the cost structure:

• $75.0 million upfront payment for IDE849 license (December 2024).
• G&A expenses for Q1 2025 were $13.5 million.
• Stock compensation for Q3 2025 was $12.2 million.
• $210 million upfront payment received from Servier for darovasertib rights (October 2025).

Finance: review the Q4 2025 projected R&D spend against the Q3 actuals by next Tuesday.

IDEAYA Biosciences, Inc. (IDYA) - Canvas Business Model: Revenue Streams

You're looking at how IDEAYA Biosciences, Inc. (IDYA) brings in cash right now, and it's heavily weighted toward partnerships, which is common for an oncology company deep in development. The revenue streams are built on upfront cash, services rendered, and the promise of future payments from those deals.

The most significant recent inflow comes from collaboration revenue, which totaled $207.8 million for the three months ended September 30, 2025. This was a big jump from zero in the prior quarter, Q2 2025. This revenue recognition is tied directly to the performance obligations satisfied under the Servier exclusive license agreement for darovasertib, which included the upfront payment received.

Another crucial component is the reimbursement for R&D services. As of September 30, 2025, IDEAYA Biosciences, Inc. had a remaining performance obligation balance of $143.1 million. This amount represents anticipated reimbursements for clinical development cost services that IDEAYA Biosciences, Inc. will perform over time under the Servier license agreement. You can expect this to convert into collaboration revenue as those research and development services are completed.

Here's a quick look at the key financial components related to the Servier deal that drive current and near-term revenue recognition:

Revenue Component	Amount/Detail	Status/Timing
Servier Upfront Payment	$210.0 million	Received, recognized as revenue over time
R&D Services Performance Obligation (RPO)	$143.1 million	Remaining balance as of Q3 2025
Total Potential Servier Milestones	Up to $320 million	Regulatory and commercial

Future royalties and commercial milestones represent the long-term upside from these partnerships. For the darovasertib ex-US rights licensed to Servier, IDEAYA Biosciences, Inc. is eligible for up to $320 million in regulatory approval-based and commercial milestone payments. On top of that, IDEAYA Biosciences, Inc. will receive double-digit royalties on net sales in all territories outside the United States. This is a defintely important stream to track.

IDEAYA Biosciences, Inc.'s revenue structure also includes milestones from other collaborations, like the one with GSK. While the upfront payment obligations for the GSK Collaboration Agreement were completed as of December 31, 2023, future collaboration revenue is still possible from earned milestones. For instance, a $7.0 million payment was earned from GSK in August 2023 based on IND acceptance for IDE705 (GSK101).

The final, and potentially largest, revenue stream is tied to IDEAYA Biosciences, Inc.'s retained US rights for darovasertib. This stream is purely potential revenue post-regulatory approval in the US. The company is advancing the drug through multiple Phase 3 registrational trials, aiming for improved patient outcomes in various settings. Success here would lead to direct product sales revenue for IDEAYA Biosciences, Inc. in the US market.

You should keep an eye on these potential US sales revenue drivers:

• Darovasertib + crizotinib in first-line HLA-A2-negative metastatic UM (mPFS readout anticipated late 2025 to Q1 2026).
• Neoadjuvant darovasertib as monotherapy in primary UM (Phase 3 trial planned for 2026).
• Future global Phase 3 adjuvant study for primary UM planned for 2026.

Finance: draft 13-week cash view by Friday.